HGH fragment 176-191: what the research shows

  • By Reed Calder
  • Last reviewed Nov 16, 2026
  • 30 studies and official documents checked

In short

HGH fragment 176-191 is the last 16 amino acids of human growth hormone, made in the lab as a peptide. The name covers more than one thing: the version one amino acid shorter, 177-191, used in most animal studies, and AOD-9604, which is 177-191 with a tyrosine added and differs from 176-191 only in its first amino acid. Vials, studies and web pages mix the three up.

When 176-191 itself was tested in normal rats in 1978, blood glucose rose briefly, insulin rose for longer, and at 5 nmol/kg insulin sensitivity fell (Ng and Bornstein, 1978). Later, 177-191 cut weight gain in obese mice, and AOD-9604 by mouth cut weight gain in obese rats by more than half, 15.8 g against 35.6 g (Natera et al., 1994; Ng et al., 2000 (AOD9604)). We found no study that gave the native 176-191 fragment to people. AOD-9604 was tested in about 900 people, and in its largest trial, about 500 adults over 24 weeks, weight loss beat placebo by less than 1 kg (2.2 lb); see the AOD-9604 page.

The FDA has approved neither one. The 2026 WADA list names both hGH 176-191 and AOD-9604 as banned growth hormone fragments.

EvidenceCellAnimalHumanrat and mouse studies; no study of the native fragment in people

You’ll often read that HGH fragment 176-191 burns fat without touching blood sugar or insulin, that it is growth hormone without the side effects, and that it is proven in clinical trials. This page covers which peptide is which, what was studied in rats, mice and cells, the usual claims checked, what the studies used, side effects, where it stands with the FDA and in sport, and what’s still unknown.

Names and forms you’ll see

The names for HGH fragment 176-191 and its relatives
Name What it is Studied in people?
HGH fragment 176-191, hGH frag 176-191, “frag 176-191” The last 16 amino acids of human growth hormone: F-L-R-I-V-Q-C-R-S-V-E-G-S-C-G-F, formula C78H123N23O22S2, 1,799.1 g/mol (PubChem CID 16131230; UniProt) We found no study
hGH 177-191, AOD-9401 One amino acid shorter, 15 in all, without the first phenylalanine: 1,651.9 g/mol. Most of the older animal studies used this one (PubChem CID 25078169; Ng et al., 2000 (AOD9401)) We found no study
AOD-9604, Tyr-hGH 177-191 The 177-191 sequence with a tyrosine added at the front, so it differs from 176-191 only in its first amino acid (tyrosine instead of phenylalanine), 1,815.1 g/mol (Cox et al., 2015; PubChem) Yes, six trials and three pain trials. See the AOD-9604 page
LAT-8881, LAT8881 The later developer’s name for AOD-9604, a synonym in the FDA’s registry (FDA GSRS) Three pain trials
Human growth hormone, somatropin The whole 191-amino-acid hormone, a prescription drug and a different compound from the fragment (UniProt) Yes, approved for several uses

CAS numbers

A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. Each number belongs to a different peptide. Suppliers sometimes list the wrong one under the name “HGH fragment 176-191”.

HGH fragment 176-191 CAS numbers
Form CAS number Registry record
hGH fragment 176-191 (starts with F) 66004-57-7 PubChem
hGH fragment 177-191 (AOD-9401) 66004-58-8 PubChem
AOD-9604 (free base) 221231-10-3 FDA GSRS

What it is

Human growth hormone, or hGH, is a protein of 191 amino acids. Its last 16, positions 176 to 191, read F-L-R-I-V-Q-C-R-S-V-E-G-S-C-G-F. The two cysteines at positions 182 and 189 are joined by a disulfide bond in the whole hormone (UniProt), and the fragment is made as a ring closed by the same bond (PubChem).

The numbers count positions in the hormone. The 177-191 version leaves out the first of the 16. AOD-9604 adds a tyrosine to the front of 177-191, which makes it 16 amino acids long, with a tyrosine where 176-191 has a phenylalanine. The two peptides differ by one oxygen atom (1,815.1 against 1,799.1 g/mol) (Cox et al., 2015; PubChem).

The names are often mixed up. The 2022 breast cancer study calls its peptide hGH fragment 176-191, but the sequence it lists, YLRIVQCRSVEGSCGF, is the AOD-9604 sequence (Habibullah et al., 2022). A 2026 review writes AOD9604 as “hGH 176-191” (Dominikowski et al., 2026).

The research started in the other direction from the way it is sold. Papers in 1978 and 1979 described the end of growth hormone as raising blood sugar in rats (Ng and Bornstein, 1978; Wade et al., 1979). By 1993 the 177-191 peptide was reported to block fat-making in rat fat tissue like the whole hormone does (Wu and Ng, 1993), and by 2000 a version was being developed as an “antiobesity drug”, the origin of the AOD name (Ogru et al., 2000).

What has been studied

We found no study that gave the native 176-191 fragment to people. PubMed lists 18 records that mention a growth hormone 176-191 or 177-191 fragment in the title or abstract (searched November 16, 2026); they are rat, mouse and cell studies, reviews and lab analyses. The tables below group them by which peptide was tested.

In normal and obese rats and mice, 1978 to 1994: 176-191 and 177-191

Studies of growth hormone 176-191 and 177-191 in rats and mice
Study Model What was used What it found
Ng and Bornstein, 1978 Normal rats Synthetic hGH 172-191, 176-191, 177-191, 178-191, 179-191 and 180-191 The first four raised blood glucose briefly and insulin for longer; the last two did nothing. At 5 nmol/kg the peptides containing 178-191 cut insulin sensitivity on an insulin tolerance test
Wade et al., 1979 Live animals (the abstract does not say which) Synthetic hGH 177-191, 178-191 and 179-191, made by solid-phase synthesis Diabetogenic activity was tested. 179-191 needed extra amino acids at the front to work, and a form of 177-191 with the ring opened was also active, so the ring was not required
Wu and Ng, 1993 Rat fat tissue hGH 177-191 Blocked fat-making as much as the whole hormone. There was no significant rise in glycerol release, the measure of fat breakdown
Wijaya and Ng, 1993 Fat cells from obese Zucker rats hGH 177-191, against whole hGH at equal amounts Lowered glucose uptake, with or without insulin, and was more potent than the whole hormone
Natera et al., 1994 Obese ob/ob mice, long-term treatment hGH 177-191 Less cumulative weight gain and less fat tissue; fat-making in fat tissue was significantly lower

EvidenceCellAnimalHumanrats and mice; these tested 176-191 or 177-191, not AOD-9604

In rats and mice, 2000 to 2001: 177-191 and AOD-9604

Studies of the 177-191 peptide and AOD-9604 in rodents
Study Model What was used What it found
Ng et al., 2000 (AOD9401) Rat fat tissue; obese Zucker rats for 20 days AOD9401, the 177-191 peptide It stimulated hormone-sensitive lipase and blocked a fat-making enzyme in fat tissue. Weight gain fell and fat cells shrank from 110 to 80 µm across. Unlike whole growth hormone, it caused no insulin resistance or glucose intolerance after long treatment
Heffernan et al., 2000 Obese ob/ob mice, 30 days (8 on saline, 10 on the peptide); human fat tissue in a dish AOD-9401 by mouth Weight gain was lower from day 16, with no difference in food eaten. Fat tissue made less fat and broke down more, and energy use and fat burning rose briefly. The same fat-breakdown and anti-fat-making changes appeared in fat tissue from obese rodents and from people
Ng et al., 2000 (AOD9604) Obese Zucker rats, 19 days AOD-9604, 500 µg/kg a day by mouth Weight gain was more than halved, 15.8 g against 35.6 g. Fat tissue broke down more fat. Insulin sensitivity was not worse on a euglycemic clamp
Heffernan et al., 2001 (mice) Obese and lean mice, 14 days by pump Whole hGH or AOD-9604 Both reduced weight gain and raised fat burning. AOD-9604 did not raise blood sugar or cut insulin release as whole growth hormone did, did not bind the growth hormone receptor and did not make cells multiply
Heffernan et al., 2001 (receptor) Obese mice, and mice lacking the fat-cell receptor beta-3 Whole hGH or AOD-9604, 14 days into the abdomen Both cut weight and fat. In mice without the beta-3 receptor, long treatment did not change weight, but an acute dose of AOD-9604 still raised energy use and fat burning

EvidenceCellAnimalHumanobese rats and mice; effects on weight gain, not on existing weight

In people: AOD-9604, not the native fragment

Human studies of AOD-9604, the modified peptide
Study Who What was used What it found
Six developer trials, 2001 to 2006 About 900 adults, mostly with obesity AOD-9604 as pills and single doses by vein, against placebo The developer’s own scientists wrote the safety summary. It reports no significant IGF-1 or glucose differences (Stier et al., 2013)
The 24-week OPTIONS trial About 500 adults with obesity AOD-9604 tablets of 0.25, 0.5 or 1 mg a day, with a supervised diet and exercise program Weight loss beat placebo by less than 1 kg (2.2 lb) at every dose, too little to reach statistical significance. The developer ended its obesity program on February 21, 2007 (company announcement, 2007)
Pain trials as LAT8881, 2019 to 2023 Three small trials of 17 to 53 people with nerve pain, migraine, or back-and-leg pain LAT8881 capsules or an infusion into a vein, against placebo None beat placebo on its main pain measure (NCT03865953; NCT04153409; NCT05298306)

The details, the FDA’s review and the safety signals are on the AOD-9604 page. They show what the 177-191-plus-tyrosine peptide did in people, not what 176-191 does.

EvidenceCellAnimalHumanAOD-9604 only; no human study of the native fragment

Cancer cells and rabbit knees

Studies of the peptide in cancer cells and rabbit knees
Study Model What was used What it found
Habibullah et al., 2022 Human MCF-7 breast cancer cells, and computer docking Chitosan nanoparticles loaded with doxorubicin and a peptide called hGH fragment 176-191 (the sequence listed is AOD-9604’s) Cell survival fell at a lower concentration with the peptide: IC50 1.5 µg/mL, against 1.85 for doxorubicin alone and 1.7 for doxorubicin-loaded nanoparticles. The peptide alone in nanoparticles was not toxic to the cells. The authors report no conflicts of interest
Kwon and Park, 2015 32 rabbits with chemically induced knee arthritis AOD-9604, 0.25 mg injected into the knee weekly, with or without hyaluronic acid Cartilage damage scores were better than with saline, and best with AOD-9604 plus hyaluronic acid. Lameness was also scored. No human study

EvidenceCellAnimalHumana cell and computer study and one small rabbit study; the peptide was AOD-9604

In lab analyses of the peptides and the products sold

Laboratory studies of the peptides and the products sold
Study What was tested What it found
Cox et al., 2015 AOD-9604 in serum and urine; vials confiscated in the U.S. AOD-9604 was found in confiscated vials. Six breakdown products formed; one, CRSVEGSCG, was much more stable than the others
Mazzarino et al., 2026 54 prohibited compounds, including hGH 176-191 and AOD-9604, in blood samples Both peptides were extensively degraded after a week in serum or plasma at 4 or 22 °C, and stayed detectable in dried samples. This measures storage of samples, not how long the peptide lasts in the body
Janvier et al., 2018 The ten falsified peptide drugs most often found on the Belgian market, bought from internet pharmacies Purity was 5% to 75% for peptides with cysteines, the amount per unit varied widely, and some samples held arsenic or lead. We did not verify whether this study included the fragment
Dominikowski et al., 2026 A 2026 review of performance-enhancing peptides For AOD-9604 it lists oral use and says no half-life was reported in human trials

EvidenceCellAnimalHumanlaboratory analyses; not studies of effects in people

The usual claims, checked

Common HGH fragment 176-191 claims vs the studies
Claim Verdict What the studies found
HGH fragment 176-191 burns fat Untested We found no study in people. In obese mice 177-191 cut weight gain and fat tissue, and AOD-9604 cut weight gain in rats. The 24-week AOD-9604 trial beat placebo by less than 1 kg, or 2.2 lb (Natera et al., 1994; Ng et al., 2000 (AOD9604); company announcement, 2007)
It removes belly fat Untested We found no study of belly or visceral fat in people given the fragment or AOD-9604 (ClinicalTrials.gov search)
It stimulates lipolysis Mixed Mixed. The 177-191 peptide stimulated lipase in rat fat tissue and raised lipolysis in human fat in a dish, and AOD-9604 raised blood glycerol in mice, but in rat fat pads 177-191 did not raise glycerol release significantly (Ng et al., 2000 (AOD9401); Heffernan et al., 2000; Heffernan et al., 2001 (mice); Wu and Ng, 1993)
It leaves blood sugar and insulin alone Mixed Mixed. In normal rats 176-191 raised blood glucose and insulin and cut insulin sensitivity at 5 nmol/kg, and 177-191 lowered glucose uptake in fat cells. Long treatment with 177-191 or AOD-9604 in obese rodents caused no insulin resistance (Ng and Bornstein, 1978; Wijaya and Ng, 1993; Ng et al., 2000 (AOD9401); Ng et al., 2000 (AOD9604))
It does not act like growth hormone Mixed Mixed. In mice AOD-9604 did not bind the growth hormone receptor or make cells multiply. We found no such test of the native fragment (Heffernan et al., 2001 (mice))
HGH fragment 176-191 is the same as AOD-9604 Contradicted No. AOD-9604 has a tyrosine where 176-191 has a phenylalanine, and the two have different registry numbers and weights (PubChem; PubChem)
It has been tested in people Contradicted We found no study of the native fragment. AOD-9604 was tested in about 900 people and in three pain trials, with weight loss under 1 kg (2.2 lb) beyond placebo in the largest trial (Stier et al., 2013; company announcement, 2007)
It fights breast cancer Untested One cell study. Nanoparticles with the peptide, whose sequence was AOD-9604’s, were toxic to cells at a lower dose than doxorubicin alone. No animal or human study (Habibullah et al., 2022)
It lasts only minutes in the body Untested We found no measurement of how long it lasts in animals or people. The only stability data are of samples kept in a dish (Mazzarino et al., 2026; Dominikowski et al., 2026)
HGH fragment 176-191 is FDA-approved Contradicted No. We found no Drugs@FDA application and no drug listing under that name (openFDA; openFDA NDC)
Research-grade HGH fragment contains the amount on the label Untested We found no analysis of this product. A study of falsified peptide drugs found purity of 5% to 75% for peptides with cysteines, which the fragment has (Janvier et al., 2018)
It is banned in sport Supported Yes. The 2026 WADA list, section S2.2.3, names hGH 176-191 and AOD-9604, prohibited at all times (WADA, 2026)

Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.

What the studies used

Amounts used in the studies
Study What was tested Amount and route
Ng and Bornstein, 1978 Normal rats 5 nmol/kg of body weight, one dose, for the insulin tolerance test
Ng et al., 2000 (AOD9604) Obese Zucker rats, AOD-9604 500 µg/kg a day by mouth for 19 days
Heffernan et al., 2000 Obese ob/ob mice, AOD-9401 By mouth for 30 days
Heffernan et al., 2001 (mice) Obese and lean mice Mini-osmotic pumps for 14 days
Kwon and Park, 2015 Rabbit knees, AOD-9604 0.25 mg into the knee joint weekly

Every amount above is an animal amount. We found no human dose of the native fragment, and the human trials above used AOD-9604 pills, single doses into a vein and infusions. Nothing here is a dosing recommendation, and we don’t repeat vial sizes or cycle lengths from seller pages.

Side effects and safety

  • In people. We found no study that gave the native fragment to people, so there are no human side-effect data for it. The human AOD-9604 trials are summarized on the AOD-9604 page.
  • Blood sugar and insulin. In normal rats the 176-191 peptide raised blood glucose briefly and insulin for longer and cut insulin sensitivity at 5 nmol/kg, and 177-191 was diabetogenic in other rat tests and lowered glucose uptake in fat cells (Ng and Bornstein, 1978; Wade et al., 1979; Wijaya and Ng, 1993). In obese rodents, long treatment with 177-191 or AOD-9604 caused no insulin resistance (Ng et al., 2000 (AOD9401); Ng et al., 2000 (AOD9604)). Different peptides, animals, doses and times, so the studies can’t be added together.
  • Compounding safety signals. The FDA’s page of bulk substances that may present significant risks names AOD-9604, not hGH 176-191: compounded AOD-9604 may carry a significant risk of immunogenicity for certain routes and has peptide-related impurities and characterization problems (FDA, 2026).
  • Product quality. A study of the ten falsified peptide drugs most often found in Belgium found 5% to 75% purity for peptides with cysteines, and arsenic and lead in some samples. We don’t know whether it included this peptide (Janvier et al., 2018).
  • Not known. Whether the native fragment does anything in people, what it does to blood sugar in people, how long it lasts, and what is in vials sold now. Side effects people report online aren’t covered here; they come from users, not studies.

Legal and approval status

  • Not approved. We found no Drugs@FDA application for HGH fragment 176-191 or AOD-9604, and no drug listing under the names “hGH fragment” or “176-191”. The FDA’s drug directory lists AOD-9604 powders as bulk ingredients, which isn’t an approval (openFDA; openFDA NDC).
  • Compounding. The FDA’s risk page, current as of April 22, 2026, names AOD-9604. Neither hGH 176-191 nor AOD-9604 is named in the FDA’s list of bulk substances nominated for compounding under section 503A, updated May 14, 2026 (FDA page; FDA document). We did not research whether pharmacies may lawfully compound it.
  • Not in the HHS policy. The October 2026 temporary policy covers six other peptides, not this one (Reuters, 2026).
  • Other countries. We did not check how other countries regulate it.
  • Research-use vials. Products labeled “research use only” aren’t approved for use in people.
  • Sport. The World Anti-Doping Agency’s 2026 list, section S2.2.3, names growth hormone fragments, including AOD-9604 and hGH 176-191, prohibited at all times (WADA, 2026).

What to look for if you research it

We don’t name or link sellers. These checks come from the studies and from the FDA:

  • Which peptide. Ask for the sequence and mass. 176-191 is FLRIVQCRSVEGSCGF at 1,799.1 g/mol, AOD-9604 is YLRIVQCRSVEGSCGF at 1,815.1, and 177-191 is 1,651.9. A listing that gives the wrong registry number may be the wrong peptide.
  • “Clinical trials.” The trials were of AOD-9604, and the largest beat placebo by under 1 kg (2.2 lb). None tested the native fragment.
  • “No effect on blood sugar.” The earliest test of 176-191 in rats found the opposite. The later no-effect results came from long treatment of obese rodents with 177-191 and AOD-9604.
  • “Burns belly fat.” No study looked at belly fat in people.
  • “Cycle length” and dose. No study gave a person a dose or a schedule. The animal amounts are per kilogram of a rat.
  • “99% pure.” Ask for a batch report that checks the sequence and mass. Falsified peptide drugs have been found at 5% to 75% purity.
  • Competition. The 2026 WADA list names it.

Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite.

Trials under way

We found no trial of HGH fragment 176-191 or AOD-9604 that is recruiting or active, so there is nothing to list on our recruiting or in-progress pages. ClinicalTrials.gov searches on November 16, 2026 found no record for “176-191”, “hGH fragment” or AOD9604, and three completed pain trials under the name LAT8881, covered on the AOD-9604 page (search). The 2001 to 2006 obesity trials predate most registry records. A registry search isn’t proof that no unregistered study exists.

What’s still unknown

  • Whether the native 176-191 fragment does anything for fat loss in people; we found no study that gave it to anyone.
  • What it does to blood sugar and insulin in people, given the 1978 rat findings.
  • Whether results with 177-191 and AOD-9604 apply to 176-191, which differs by one amino acid at the front.
  • How long it lasts in the body; we found no measurement.
  • What is in the vials sold as HGH fragment 176-191 now; we found no analysis of them.

Retracted and flagged studies

A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.

We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention HGH fragment 176-191. We recheck every month. Last checked Nov 16, 2026.

We found no retracted, withdrawn or flagged studies that mention HGH fragment 176-191.

Studies this page relies on

Status of every study cited on this page
Study Published in Status
Wade et al., 1979 Int J Pept Protein Res No retraction or concern
Ng and Bornstein, 1978 Am J Physiol No retraction or concern
Natera et al., 1994 Biochem Mol Biol Int No retraction or concern
Wijaya and Ng, 1993 Biochem Mol Biol Int No retraction or concern
Wu and Ng, 1993 Biochem Mol Biol Int No retraction or concern
Heffernan et al., 2000 Am J Physiol Endocrinol Metab No retraction or concern
Ng et al., 2000 J Mol Endocrinol No retraction or concern
Ng et al., 2000 Horm Res No retraction or concern
Ogru et al., 2000 J Pept Res No retraction or concern
Heffernan et al., 2001 Int J Obes Relat Metab Disord No retraction or concern
Heffernan et al., 2001 Endocrinology No retraction or concern
Cox et al., 2015 Drug Test Anal No retraction or concern
Kwon and Park, 2015 Ann Clin Lab Sci No retraction or concern
Janvier et al., 2018 Talanta No retraction or concern
Habibullah et al., 2022 Drug Des Devel Ther No retraction or concern
Mazzarino et al., 2026 Analyst No retraction or concern
Dominikowski et al., 2026 Front Endocrinol (Lausanne) No retraction or concern

Bring your questions to other researchers

Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.

Questions

What is HGH fragment 176-191?

It is the last 16 amino acids of human growth hormone, F-L-R-I-V-Q-C-R-S-V-E-G-S-C-G-F, made in the lab as a peptide. The name is often used for related peptides too (UniProt; PubChem).

What is HGH fragment 176-191 used for?

Sellers market it for fat loss. We found no study of the native fragment in people. In 1978 it raised blood glucose and insulin in normal rats, and later work on 177-191 and AOD-9604 in obese rodents found less weight gain (Ng and Bornstein, 1978; Natera et al., 1994; Ng et al., 2000 (AOD9604)).

Is HGH fragment 176-191 the same as HGH?

No. Human growth hormone is a protein of 191 amino acids. The fragment is its last 16, made as a separate peptide (UniProt).

Is HGH fragment 176-191 the same as AOD-9604?

No, but they are close. AOD-9604 is 177-191 with a tyrosine added at the front, so it differs from 176-191 only in its first amino acid. The two have different registry numbers (Cox et al., 2015; PubChem; PubChem).

Will HGH fragment 176-191 remove belly fat?

We found no study of belly or visceral fat in people given the fragment or AOD-9604. The largest AOD-9604 trial beat placebo by less than 1 kg, or 2.2 lb, over 24 weeks (company announcement, 2007).

What are the side effects of HGH fragment 176-191?

We found no human side-effect data for the native fragment. In normal rats it raised blood glucose and insulin and cut insulin sensitivity (Ng and Bornstein, 1978).

Does HGH fragment 176-191 raise blood sugar?

In normal rats, yes: the 176-191 peptide raised blood glucose briefly and insulin for longer, and cut insulin sensitivity at 5 nmol/kg. Long treatment of obese rodents with 177-191 or AOD-9604 caused no insulin resistance (Ng and Bornstein, 1978; Ng et al., 2000 (AOD9401); Ng et al., 2000 (AOD9604)).

Does HGH fragment 176-191 raise IGF-1?

We found no study of the native fragment. In mice AOD-9604 did not bind the growth hormone receptor, and the company’s human safety summary reports no significant IGF-1 differences (Heffernan et al., 2001 (mice); Stier et al., 2013).

What dose of HGH fragment 176-191 did the studies use?

Only animal amounts: for example 5 nmol/kg in rats in 1978, and 500 µg/kg a day of AOD-9604 by mouth in obese rats. There is no human dose. See what the studies used. It is not a dosing recommendation (Ng and Bornstein, 1978; Ng et al., 2000 (AOD9604)).

How long does HGH fragment 176-191 last in the body?

We found no measurement. Samples of both the fragment and AOD-9604 degraded extensively after a week in serum or plasma at 4 or 22 °C, which is about storing samples, not the body (Mazzarino et al., 2026).

How is HGH fragment 176-191 different from tesamorelin?

They are different kinds of compound. Tesamorelin is an FDA-approved drug that makes the pituitary release growth hormone; the fragment is a piece of the hormone and has no human study. See what the research shows on tesamorelin.

Is HGH fragment 176-191 FDA-approved?

No. We found no Drugs@FDA application and no drug listing under that name (openFDA; openFDA NDC).

Is HGH fragment 176-191 banned in sport?

Yes. The 2026 WADA list, section S2.2.3, names hGH 176-191 and AOD-9604, prohibited at all times (WADA, 2026).

Are there HGH fragment 176-191 clinical trials recruiting?

We found none. ClinicalTrials.gov has no record for the fragment or AOD9604, and three completed pain trials under the name LAT8881 (search, November 16, 2026).

Sources

  1. Ng FM, Bornstein J. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol. 1978;234(5):E521-6. PubMed 645904
  2. Wade JD, Ng FM, Bornstein J. Diabetogenic action of human growth hormone. Synthesis and activity of C-terminal fragments. Int J Pept Protein Res. 1979;13(2):195-200. PubMed 429095
  3. Wu Z, Ng FM. Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. Biochem Mol Biol Int. 1993;30(1):187-96. PubMed 8358331
  4. Wijaya E, Ng FM. Effect of an antilipogenic fragment of human growth hormone on glucose transport in rat adipocytes. Biochem Mol Biol Int. 1993;31(3):543-52. PubMed 8118430
  5. Natera SH, Jiang WJ, Ng FM. Reduction of cumulative body weight gain and adipose tissue mass in obese mice: response to chronic treatment with synthetic hGH 177-191 peptide. Biochem Mol Biol Int. 1994;33(5):1011-21. PubMed 7987248
  6. Ogru E, Wilson JC, Heffernan M, et al. The conformational and biological analysis of a cyclic anti-obesity peptide from the C-terminal domain of human growth hormone. J Pept Res. 2000;56(6):388-97. PubMed 11152298
  7. Ng FM, Jiang WJ, Gianello R, et al. Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats. J Mol Endocrinol. 2000;25(3):287-98. PubMed 11116208
  8. Heffernan MA, Jiang WJ, Thorburn AW, et al. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;279(3):E501-7. PubMed 10950816
  9. Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-8. PubMed 11146367
  10. Heffernan MA, Thorburn AW, Fam B, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-9. PubMed 11673763
  11. Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-9. PubMed 11713213
  12. Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015;45(4):426-32. PubMed 26275694
  13. Habibullah MM, Mohan S, Syed NK, et al. Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells. Drug Des Devel Ther. 2022;16:1963-1974. PubMed 35783198
  14. Cox HD, Smeal SJ, Hughes CM, et al. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015;7(1):31-8. PubMed 25208511
  15. Mazzarino M, Colpaert T, Deventer K, et al. Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices. Analyst. 2026;151(15):4398-4413. PubMed 42328738
  16. Janvier S, Cheyns K, Canfyn M, et al. Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta. 2018;188:795-807. PubMed 30029448
  17. Dominikowski A, Rękoś Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475. PubMed 42395176
  18. Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 2013;3(1-2):7-15. Journal page
  19. Metabolic Pharmaceuticals Limited. Metabolic’s obesity drug - Phase 2B clinical trial results. ASX announcement, February 21, 2007. Announcement
  20. ClinicalTrials.gov. Searches for “176-191”, “hGH fragment”, AOD9604, AOD-9604 and “growth hormone fragment”, November 16, 2026: no record; three completed pain trials under the name LAT8881 (NCT03865953, NCT04153409, NCT05298306). Search
  21. World Anti-Doping Agency. 2026 Prohibited List, section S2.2.3 (growth hormone fragments, including AOD-9604 and hGH 176-191). WADA document
  22. U.S. Food and Drug Administration. openFDA Drugs@FDA: searches for hGH fragment and AOD-9604 found no application, November 16, 2026. openFDA
  23. U.S. Food and Drug Administration. openFDA drug listings (NDC): no listing under “hGH fragment” or “176-191”; AOD-9604 powders are listed as bulk ingredients, November 16, 2026. openFDA NDC
  24. U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding (content current as of April 22, 2026; AOD-9604 named, hGH 176-191 not named). FDA page
  25. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A: categories, updated May 14, 2026 (neither AOD-9604 nor hGH 176-191 named). FDA document
  26. Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
  27. UniProt. Somatotropin, human (P01241): the 191-amino-acid hormone (residues 27 to 217 of the precursor) and its disulfide bonds. UniProt
  28. National Library of Medicine. PubChem compound record: hGH fragment 176-191 (starts with F) (CID 16131230). PubChem
  29. National Library of Medicine. PubChem compound record: hGH fragment 177-191 (AOD-9401) (CID 25078169). PubChem
  30. U.S. Food and Drug Administration. Global Substance Registration System: AOD-9604 (UNII 7UP768IP4M). GSRS

Last reviewed Nov 16, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.